[14C]-BGB-16673 for Healthy Subjects

Recruiting in Palo Alto (17 mi)

Age: 18 - 65

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: BeiGene

Disqualifiers: Metabolic, Cardiovascular, Psychiatric, others

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this study is to determine the absorption, metabolism, and excretion of \[14C\]-BGB-16673 and to characterize and determine, where possible, the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, since the study involves healthy participants and excludes those with significant medical conditions, it's likely that participants should not be on any regular medications.

Eligibility Criteria

This trial is for healthy men with a BMI between 18.0 and 32.0, who have at least one bowel movement daily, can understand and sign the consent form, and have no significant medical history findings.

Inclusion Criteria

I have at least one bowel movement daily.

I understand and agree to follow the study rules.

My BMI is between 18.0 and 32.0.

+1 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive a single oral dose of [14C]-BGB-16673

1 day

Metabolism and Excretion Monitoring

Participants are monitored for absorption, metabolism, and excretion of the drug, with sample collection from plasma, urine, and feces

1-2 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks

Participant Groups

[14C]-BGB-16673 is being tested to see how it's absorbed, metabolized, and excreted after a single oral dose in healthy participants. The study will track this drug in blood, urine, and feces.

1Treatment groups

Experimental Treatment

Group I: Single Arm: [14C]-BGB-16673Experimental Treatment1 Intervention

Participants will receive a single dose of \[14C\]-BGB-16673